CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $2.4M market cap.
Most recent earnings call: Q2 FY22 on Aug 12, 2022.
6 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks CASIF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CASIF.
$ curl https://api.spokenalpha.com/v1/companies/CASIFFAQ
Spoken Alpha indexes CASIF's earnings call transcripts at https://spokenalpha.com/companies/CASIF. Each call links to attributed speakers and parsed analyst Q&A.
CASI Pharmaceuticals, Inc. (CASIF) held its most recent earnings call on 2022-08-12, covering fiscal Q2 2022.
CASI Pharmaceuticals, Inc. (CASIF) operates in the Healthcare sector (Biotechnology industry).
When a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2022 | $6.14 | $4.22 | +45.6% | -0.2% | +2.6% |
| Q4 FY2022 | $6.12 | $4.34 | +40.9% | -0.4% | +2.6% |
| Q3 FY2022 | $6.04 | $4.26 | +41.9% | -6.4% | -4.5% |
| Q2 FY2022 | $6.51 | $4.42 | +47.2% | +1.1% | +2.7% |
| Q1 FY2021 | $6.39 | $4.46 | +43.2% | -7.6% | -8.2% |
| Q4 FY2021 |
| $6.53 |
| $4.50 |
| +45.1% |
| +3.2% |
| +2.0% |
| Q3 FY2021 | $6.36 | $4.53 | +40.3% | -3.7% | -3.3% |
| Q2 FY2021 | $6.47 | $4.62 | +40.0% | -4.0% | -2.1% |
| Q1 FY2020 | $6.07 | $4.46 | +36.2% | -3.3% | -4.8% |
| Q4 FY2020 | $6.64 | $4.58 | +45.0% | +0.2% | -2.5% |